Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Share:
Related GSK
GlaxoSmithKline And Innoviva Plan To File A NDA For Triple Combination Therapy
GlaxoSmithKline, Innoviva Offer Regulatory Update on US Filing Plans for Closed Triple Combo Therapy FF/UMEc/VI for Patients with COPD
Transnational Companies - More Reliable Than Countries Right Now (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

View Comments and Join the Discussion!